New emapalumab data presented at Transplantation and Cellular Therapy (TCT) Meeting highlight post-transplant treatment outcomes in primary HLH
Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) at the 2019 Transplantation and Cellular Therapy (TCT) Meetings, February 20-24 in Houston, Texas. The data examine the outcomes of primary HLH patients who were treated with emapalumab and proceeded to haematopoietic stem cell transplantation (HSCT).